REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
We assign a fundamental rating of 3 out of 10 to RPTX. RPTX was compared to 568 industry peers in the Biotechnology industry. While RPTX has a great health rating, there are worries on its profitability. While showing a medium growth rate, RPTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RPTX had negative earnings in the past year.
RPTX had a negative operating cash flow in the past year.
RPTX had negative earnings in each of the past 5 years.
RPTX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
RPTX has a Return On Assets of -36.92%. This is in the better half of the industry: RPTX outperforms 60.18% of its industry peers.
The Return On Equity of RPTX (-44.20%) is better than 70.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROIC | N/A |
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RPTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RPTX has more shares outstanding
The number of shares outstanding for RPTX has been increased compared to 5 years ago.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RPTX has an Altman-Z score of -1.37. This is a bad value and indicates that RPTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.37, RPTX perfoms like the industry average, outperforming 56.81% of the companies in the same industry.
RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.37 |
ROIC/WACCN/A
WACC10.53%
2.3 Liquidity
A Current Ratio of 6.24 indicates that RPTX has no problem at all paying its short term obligations.
RPTX has a Current ratio of 6.24. This is in the better half of the industry: RPTX outperforms 63.19% of its industry peers.
RPTX has a Quick Ratio of 6.24. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
RPTX's Quick ratio of 6.24 is fine compared to the rest of the industry. RPTX outperforms 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 |
3. Growth
3.1 Past
RPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.42%, which is quite good.
RPTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.20%.
The Revenue has been growing by 699.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 13.36% on average over the next years. This is quite good.
Based on estimates for the next years, RPTX will show a quite strong growth in Revenue. The Revenue will grow by 10.54% on average per year.
EPS Next Y1.96%
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%
EPS Next 5Y13.36%
Revenue Next Year-7.38%
Revenue Next 2Y-66.9%
Revenue Next 3Y-32.03%
Revenue Next 5Y10.54%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%
5. Dividend
5.1 Amount
No dividends for RPTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPARE THERAPEUTICS INC
NASDAQ:RPTX (12/20/2024, 8:00:01 PM)
After market: 1.33 +0.01 (+0.76%)1.32
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.17%
Inst Owner Change-8.8%
Ins Owners1.09%
Ins Owner Change0%
Market Cap56.11M
Analysts81.54
Price Target12.75 (865.91%)
Short Float %1.49%
Short Ratio1.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.28%
Min EPS beat(2)-83.19%
Max EPS beat(2)48.63%
EPS beat(4)2
Avg EPS beat(4)7.4%
Min EPS beat(4)-83.19%
Max EPS beat(4)64.81%
EPS beat(8)4
Avg EPS beat(8)39.51%
EPS beat(12)5
Avg EPS beat(12)23.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-49.44%
Min Revenue beat(2)-66.45%
Max Revenue beat(2)-32.43%
Revenue beat(4)1
Avg Revenue beat(4)44.51%
Min Revenue beat(4)-66.45%
Max Revenue beat(4)285.98%
Revenue beat(8)3
Avg Revenue beat(8)878.58%
Revenue beat(12)5
Avg Revenue beat(12)593.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.85%
PT rev (3m)-8.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)2.75%
EPS NY rev (3m)5.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-4.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | 0.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS1.2
BVpS4.99
TBVpS4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 99.33% | ||
| Cap/Sales | 3.79% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 | ||
| Altman-Z | -1.37 |
F-Score2
WACC10.53%
ROIC/WACCN/A
Cap/Depr(3y)81.53%
Cap/Depr(5y)141.32%
Cap/Sales(3y)8.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y1.96%
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%
EPS Next 5Y13.36%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-7.38%
Revenue Next 2Y-66.9%
Revenue Next 3Y-32.03%
Revenue Next 5Y10.54%
EBIT growth 1Y-490.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.24%
EBIT Next 3Y-19.95%
EBIT Next 5YN/A
FCF growth 1Y-46005.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39836.9%
OCF growth 3YN/A
OCF growth 5YN/A